Compare Trip.com Group Ltd (TCOM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Trip.com Group Ltd trades at $43.78 (market cap $28.12B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Trip.com Group Ltd pays a 0.42% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Trip.com Group Ltd nearer its low. Which is the better fit depends on your goals.
| TCOM | XBI | |
|---|---|---|
Market Cap | $28.12B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $78.96 | $164.28 |
52-Week Low | $39.84 | $85.16 |
Enterprise Value | $20.82B | — |
Dividend Yield | 0.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
